AgeX Therapeutics (NYSEAM:AGE) - Hisse Senedi Fiyatı, Haberler ve Analizler

AGE Stoklara Genel Bakış

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. Daha fazla detay

AGE temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Risk Analizi

1 yıldan az nakit akışı var

Geliri 1 milyon ABD dolarından az ( $142K )

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Kazançlar son 5 yılda yılda 2.6% oranında azaldı

+ 2 daha fazla risk

AgeX Therapeutics, Inc. Rakipler

Gain Therapeutics

NasdaqGM:GANX

US$45.9m

Shattuck Labs

NasdaqGS:STTK

US$51.6m

Affimed

NasdaqGM:AFMD

US$47.0m

Homology Medicines

NasdaqGS:FIXX

US$54.3m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti AgeX Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$11.10
52 Haftanın En Yüksek Seviyesi	US$35.17
52 Haftanın En Düşük Seviyesi	US$10.90
Beta	1.19
11 Aylık Değişim	-14.70%
3 Aylık Değişim	-23.49%
1 Yıllık Değişim	-48.68%
33 Yıllık Değişim	-80.64%
5 Yıllık Değişim	-92.39%
Halka arzdan bu yana değişim	-88.35%

Son Haberler & Güncellemeler

Recent updates

Here's What AgeX Therapeutics, Inc.'s (NYSEMKT:AGE) Shareholder Ownership Structure Looks Like

Feb 09

Does AgeX Therapeutics' (NYSEMKT:AGE) Share Price Gain of 14% Match Its Business Performance?

Nov 20

Hissedar Getirileri

	AGE	US Biotechs	US Pazar
7D	-23.6%	4.3%	1.6%
1Y	-48.7%	18.8%	32.3%

Getiri vs. Endüstri: AGE geçen yıl % 18.8 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: AGE geçen yıl % 32.3 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is AGE's price volatile compared to industry and market?
AGE volatility
AGE Average Weekly Movement	18.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: AGE hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: AGE 'nin haftalık oynaklığı ( 18% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2017	6	Joanne Hackett	www.agexinc.com

AgeX Therapeutics, Inc. Temel Bilgiler Özeti

AgeX Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
AGE temel i̇stati̇sti̇kler
Piyasa değeri	US$31.51m
Kazançlar(TTM)	-US$14.80m
Gelir(TTM)	US$142.00k

195.5x

P/S Oranı

-1.9x

F/K Oranı

AGE aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
AGE gelir tablosu (TTM)
Gelir	US$142.00k
Gelir Maliyeti	US$40.00k
Brüt Kâr	US$102.00k
Diğer Giderler	US$14.91m
Kazançlar	-US$14.80m

Son Raporlanan Kazançlar

Dec 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-5.92
Brüt Marj	71.83%
Net Kâr Marjı	-10,424.65%
Borç/Özkaynak Oranı	81.5%

AGE uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

AGE Stoklara Genel Bakış

Risk Analizi

AgeX Therapeutics, Inc. Rakipler

NasdaqGM:GANX

US$45.9m

NasdaqGS:STTK

US$51.6m

NasdaqGM:AFMD

US$47.0m

NasdaqGS:FIXX

US$54.3m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. (NYSEAM:AGE) from a group of shareholders in a reverse merger transaction.

AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee

Agex Therapeutics, Inc. Terminates Nafees Malik as Chief Operating Officer, Effective on December 27, 2023

AgeX Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. (NYSEAM:AGE) from shareholders in a reverse merger transaction.

Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. (NYSEAM:AGE) from shareholders in a reverse merger transaction.

Recent updates

Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. (NYSEAM:AGE) from a group of shareholders in a reverse merger transaction.

AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee

Agex Therapeutics, Inc. Terminates Nafees Malik as Chief Operating Officer, Effective on December 27, 2023

AgeX Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. (NYSEAM:AGE) from shareholders in a reverse merger transaction.

Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. (NYSEAM:AGE) from shareholders in a reverse merger transaction.

Agex Therapeutics Provides Non-Compliance Update Related to Stock Holders Equity

AgeX Therapeutics Announces Appeal of NYSE American Determination

NYSE American to Suspend Trading Immediately in Agex Therapeutics and Commence Delisting Proceedings

Third quarter 2022 earnings released: US$0.064 loss per share (vs US$0.052 loss in 3Q 2021)

AgeX Therapeutics, Inc., Annual General Meeting, Dec 07, 2022

Second quarter 2022 earnings released: US$0.069 loss per share (vs US$0.065 loss in 2Q 2021)

AgeX Therapeutics, Inc. Announces Board Changes

First quarter 2022 earnings released: US$0.071 loss per share (vs US$0.053 loss in 1Q 2021)

Full year 2021 earnings released: US$0.23 loss per share (vs US$0.29 loss in FY 2020)

AgeX Therapeutics, Inc. to Report Q4, 2021 Results on Mar 29, 2022

AgeX Therapeutics, Inc. to Report Q4, 2021 Results on Mar 29, 2022

AgeX Therapeutics, Inc. announced that it expects to receive $13.16 million in funding from Juvenescence Ltd.

Less than half of directors are independent

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

Third quarter 2021 earnings released: US$0.052 loss per share (vs US$0.067 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.065 loss per share (vs US$0.071 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.053 loss per share (vs US$0.085 loss in 1Q 2020)

Full year 2020 earnings released: US$0.29 loss per share (vs US$0.33 loss in FY 2019)

Agex Therapeutics to Collaborate with the Ohio State University to Generate Proof-Of-Concept Animal Data for Agex’s Brown Adipose Tissue (Bat) Cell Therapy Candidate for Diabetes and Obesity

Atlas Capital Group Ltd. entered into an agreement to acquire LifeMap Sciences Ltd from AgeX Therapeutics, Inc. (AMEX:AGE).

Here's What AgeX Therapeutics, Inc.'s (NYSEMKT:AGE) Shareholder Ownership Structure Looks Like

New 90-day high: US$2.06

AgeX Therapeutics, Inc.(AMEX:AGE) dropped from Russell 2000 Dynamic Index

New 90-day high: US$1.94

AgeX Therapeutics, Inc., Annual General Meeting, Dec 28, 2020

Does AgeX Therapeutics' (NYSEMKT:AGE) Share Price Gain of 14% Match Its Business Performance?

Third quarter 2020 earnings released: US$0.067 loss per share

New 90-day high: US$2.48

First half earnings released

New 90-day high - US$1.52

AgeX Therapeutics, Inc.(AMEX:AGE) dropped from Russell 2000 Dynamic Index

AgeX Therapeutics, Inc.(AMEX:AGE) dropped from Russell 3000 Growth Index

AgeX Therapeutics, Inc.(AMEX:AGE) dropped from Russell Microcap Index

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

AgeX Therapeutics, Inc. Temel Bilgiler Özeti

195.5x

-1.9x

Kazanç ve Gelir